NCT03457142View on ClinicalTrials.gov

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 11, 2018

Primary Completion Date

November 21, 2022

Study Completion Date

November 6, 2024

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
BIOLOGICAL

Abatacept

Given IV and SC

DRUG

Dexamethasone

Given PO

DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (3)

11548

St. Francis Hospital, East Hills

11795

Good Samaritan Hospital, West Islip

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER